Liquidia Technologies AI Stock Analysis
Want to see LQDA full AI Analyst Report?
Liquidia Technologies (LQDA) AI Stock Analysis
Liquidia Technologies
(NASDAQ:LQDA)
Overall score reflects solid fundamental momentum led by sharply improved cash generation and strong commercial execution highlighted on the earnings call, partly offset by balance-sheet risk from negative equity and still-negative profitability. Technicals are currently a headwind with the stock below key longer-term moving averages, while valuation (P/E 30.5 and no dividend) implies growth expectations remain elevated.
Liquidia Technologies Key Performance Indicators (KPIs)
Gross Profit by TypeShows gross profit split across product sales, contract manufacturing/services, and licensing or milestone income. For Liquidia Technologies, it reveals which revenue streams generate real profit versus those that are low-margin or one-time, indicating how sustainable earnings are and how much scale or pricing power the company needs to become consistently profitable.
Product gross profit is the clear driver now—rising into Q2 2026 and tracking with the company’s rapid YUTREPIA sales and improved EBITDA/cash generation; the earlier multi‑billion spikes look like data anomalies or reclassifications and shouldn’t obscure the recent, repeatable margin build. Service gross profit has effectively collapsed to near zero, signaling a deliberate shift to a product‑centric model (or a reclassification) that amplifies upside from market share gains but also concentrates execution and legal/patent risk on YUTREPIA as R&D and SG&A ramp.
The FlyLiquidia Technologies (LQDA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.94B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.53M
- Price to Earnings (P/E)
- -53.6
- Beta (1Y)
- 1.50
- Revenue Growth
- 798.44%
- EPS Growth
- 27.88%
- Country
- US
- Employees
- 216
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Liquidia Technologies Business Overview & Revenue Model
Company Description
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset i...
Liquidia Technologies Earnings Call Summary
The call was strongly positive overall. Management reported accelerating YUTREPIA sales, five consecutive quarters of growth, record October shipments, expanding PAH adoption, strong adjusted EBITDA, improving operating leverage and a balance sheet sufficient to fund planned activities. The main negatives were the settlement-related GAAP loss and cash obligations, temporary referral disruption from litigation uncertainty, the PAH-only indication, increased R&D spending and the unresolved timing of 2027 guidance. The number and magnitude of the operating and commercial positives outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Liquidia expects conversion rates to remain greater than 87%, daily referrals in October were more than 75% of the daily rate in Q3, and October represents a floor and not a trend; it expects shipments, patient stacking and profitability to continue to grow quarter-on-quarter, with more information about 2027 expectations probably in early January. SPRINT is expected to initiate at the end of this year and is looking to achieve at least a 20% to 25% change in PVR, EASY-PAH is planned for 2027, RE-WARM is expected to complete in the first half of 2027 with a pivotal study possible during the following winter seasons, Re-Spire enrollment is expected to complete in 2028, AMPLIFY-PAH will initiate in 2027, data from both studies are expected to support a 505(b)(1) NDA submission in 2029, and a PH-COPD pivotal study is planned for the second half of next year; the company said it has no need to raise extra capital and is not changing its operating plan.
Liquidia Technologies Financial Statement Overview
Summary
Financials are mixed. Income statement reflects a major revenue step-up and very high gross margin, but EBIT/EBITDA and net income are still negative. Cash flow is a clear strength with operating and free cash flow turning strongly positive. The balance sheet is the key risk, with stockholders’ equity turning negative, limiting flexibility despite lower debt.
Income Statement
62PositiveBalance Sheet
34NegativeCash Flow
81Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 621.87M | 158.32M | 14.00M | 17.49M | 15.94M | 12.85M |
| Gross Profit | 576.33M | 145.08M | 8.12M | 14.60M | 13.08M | 9.83M |
| EBITDA | -89.03M | -43.22M | -115.71M | -70.05M | -35.03M | -28.20M |
| Net Income | -94.19M | -68.92M | -130.39M | -78.50M | -41.02M | -34.58M |
Balance Sheet | ||||||
| Total Assets | 682.94M | 327.93M | 230.31M | 118.33M | 129.20M | 93.73M |
| Cash, Cash Equivalents and Short-Term Investments | 396.09M | 190.68M | 176.48M | 83.68M | 93.28M | 57.49M |
| Total Debt | 168.76M | 197.93M | 122.39M | 49.54M | 24.46M | 16.08M |
| Total Liabilities | 708.38M | 283.19M | 153.04M | 71.04M | 38.78M | 28.46M |
| Stockholders Equity | -25.43M | 44.75M | 77.28M | 47.29M | 90.42M | 65.27M |
Cash Flow | ||||||
| Free Cash Flow | 200.97M | -40.02M | -98.37M | -42.85M | -29.18M | -34.14M |
| Operating Cash Flow | 235.48M | -35.69M | -93.42M | -41.56M | -28.59M | -34.03M |
| Investing Cash Flow | -39.51M | -6.34M | -8.44M | -11.29M | -587.00K | -107.00K |
| Financing Cash Flow | 28.23M | 59.73M | 194.66M | 43.25M | 64.96M | 26.32M |
Liquidia Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LQDA, the sentiment is Positive. The current price of 55.21 is above the 20-day moving average (MA) of 43.03, above the 50-day MA of 49.42, and above the 200-day MA of 54.56, indicating a bullish trend. The MACD of 1.26 indicates Negative momentum. The RSI at 65.76 is Neutral, neither overbought nor oversold. The STOCH value of 84.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LQDA.
Liquidia Technologies Risk Analysis
Liquidia Technologies disclosed 70 risk factors in its most recent earnings report. Liquidia Technologies reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksLiquidia Technologies Peers Comparison
Overall Rating
KNSA80Outperform
CORT72Outperform- LQDA63Neutral
SCYX53Neutral
NSRX28Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KNSA | 80Outperform | $7.47B | 66.97 | 17.27% | ― | 58.19% | 192.34% |
| CORT | 72Outperform | $8.03B | 49.69 | 22.94% | ― | 30.02% | 48.80% |
| LQDA | 63Neutral | $4.60B | -53.60 | -116.64% | ― | 798.44% | 27.88% |
| SCYX | 53Neutral | $35.04M | -2.92 | -18.65% | ― | 543.96% | 72.49% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NSRX | 28Underperform | $34.96M | -2.83 | -158.83% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LQDA | Liquidia Technologies | 55.21 | 28.27 | 104.94% | |
| CORT | Corcept Therapeutics | 74.53 | -1.22 | -1.61% | |
| SCYX | SCYNEXIS Inc | 3.42 | -1.30 | -27.65% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. Class A | 95.76 | 55.47 | 137.68% | |
| NSRX | Nasus Pharma Ltd. | 2.91 | -4.99 | -63.16% | |
| CUVL | Clinuvel Pharmaceuticals Limited Sponsored ADR | 5.09 | -2.12 | -29.39% |
Liquidia Technologies Corporate Events
Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth
PositiveLiquidia Corporation is a biopharmaceutical company developing treatments for challenging respiratory and vascular diseases, including YUTREPIA inhalation powder. On November 10, 2026, it reported third-quarter net product sales of $222.7 million for...
Liquidia Reaches Global Patent Settlement, Refines Financing
NegativeOn Oct. 13, 2026, Liquidia Technologies and United Therapeutics entered a global settlement that resolves all ongoing patent, trade secret, contract and antitrust litigation between the companies, following a September court ruling that YUTREPIA infr...
Liquidia Faces Adverse Patent Ruling on YUTREPIA
NegativeOn September 30, 2026, Liquidia reported that the U.S. District Court for the District of Delaware found two of six asserted claims of United Therapeutics’ U.S. Patent No. 11,826,327 valid and infringed by YUTREPIA, specifically those covering treatm...
Liquidia Gains FDA Fast Track for YUTREPIA in Raynaud’s
PositiveOn September 3, 2026, Liquidia Corporation announced that the U.S. Food and Drug Administration granted Fast Track designation to its inhaled treprostinil powder YUTREPIA for the treatment of Raynaud’s phenomenon associated with systemic sclerosis, a...
Liquidia Technologies reports strong Q2 growth and profitability
PositiveOn August 12, 2026, Liquidia Corporation reported strong second quarter 2026 results driven by rapid uptake of YUTREPIA, its inhaled treprostinil powder. Net product sales reached $170.4 million, up 31% from the prior quarter, with about 5,900 unique...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026